These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report. DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133 [No Abstract] [Full Text] [Related]
43. Can gadolinium be safely given in renal failure? Weissleder R AJR Am J Roentgenol; 1996 Jul; 167(1):278-9. PubMed ID: 8659405 [No Abstract] [Full Text] [Related]
44. Severe anaphylactoid reaction to Gd-DTPA. Lufkin RB Radiology; 1990 Sep; 176(3):879. PubMed ID: 2389057 [No Abstract] [Full Text] [Related]
45. Acute renal failure after arteriography with a gadolinium-based contrast agent. Gemery J; Idelson B; Reid S; Yucel EK; Pagan-Marin H; Ali S; Casserly L AJR Am J Roentgenol; 1998 Nov; 171(5):1277-8. PubMed ID: 9798860 [No Abstract] [Full Text] [Related]
51. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. Kane GC; Stanson AW; Kalnicka D; Rosenthal DW; Lee CU; Textor SC; Garovic VD Nephrol Dial Transplant; 2008 Apr; 23(4):1233-40. PubMed ID: 18256017 [TBL] [Abstract][Full Text] [Related]
52. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233 [TBL] [Abstract][Full Text] [Related]
53. MultiHance for dynamic MR imaging of the breast. Sardanelli F Eur Radiol; 2004 Jun; 14 Suppl 7():O65-70; discussion O84-5. PubMed ID: 15503379 [No Abstract] [Full Text] [Related]
55. Editorial for "Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine and Gadobutrol to rats". Liang X; Yeh CH J Magn Reson Imaging; 2021 Nov; 54(5):1645-1646. PubMed ID: 34046961 [No Abstract] [Full Text] [Related]
56. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections. Abujudeh HH; Kosaraju VK; Kaewlai R AJR Am J Roentgenol; 2010 Feb; 194(2):430-4. PubMed ID: 20093606 [TBL] [Abstract][Full Text] [Related]
57. Gadolinium-induced anaphylaxis with positive skin test results. Rodriguez-Nava G; Kesler AM; Carrillo-Martin I; Gonzalez-Estrada A Ann Allergy Asthma Immunol; 2019 Jun; 122(6):654-655. PubMed ID: 30926309 [No Abstract] [Full Text] [Related]
58. Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure. Shahid I; Joseph A; Lancelot E Invest Radiol; 2022 Oct; 57(10):664-673. PubMed ID: 35471204 [TBL] [Abstract][Full Text] [Related]
59. Safety of gadoteridol injection: U.S. clinical trial experience. Olukotun AY; Parker JR; Meeks MJ; Lucas MA; Fowler DR; Lucas TR J Magn Reson Imaging; 1995; 5(1):17-25. PubMed ID: 7696805 [TBL] [Abstract][Full Text] [Related]
60. Indirect MR lymphangiography of the head and neck using conventional gadolinium contrast: a pilot study in humans. Loo BW; Draney MT; Sivanandan R; Ruehm SG; Pawlicki T; Xing L; Herfkens RJ; Le QT Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):462-8. PubMed ID: 16965993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]